RESUMEN
PURPOSE: Sepsis after transrectal ultrasound guided prostate biopsy is an increasing problem in this era of rising antibiotic resistance. Although ertapenem prophylaxis has proved effective at our institution to reduce this, it has raised local and regional antimicrobial stewardship concerns. We investigated the possible selective effect of single dose ertapenem prophylaxis on fecal colonization with carbapenem resistant Enterobacteriaceae. MATERIALS AND METHODS: Patients underwent a rectal swab prior to receiving prebiopsy ertapenem prophylaxis. A second swab was obtained at followup 4 to 6 weeks later. Swabs were screened for carbapenem resistant Enterobacteriaceae using an enhanced CDC (Centers for Disease Control) method. Prebiopsy swabs were also screened for extended spectrum ß-lactamase producing and ciprofloxacin resistant Enterobacteriaceae. Patients were monitored for post-biopsy sepsis. RESULTS: A total of 326 patients were enrolled in the study. At baseline 6.4% and 9.0% of patients had colonization with extended spectrum ß-lactamase producing and ciprofloxacin resistant Enterobacteriaceae, respectively. Carbapenem resistant Enterobacteriaceae were not detected at baseline or followup in any patients. Colonization with nonfermentative organisms with intrinsic ertapenem resistance was detected in 29.4% of patients at baseline and followup (p = 1.0). Three cases (0.9%, 95% CI 0.2-2.8) of probable post-biopsy sepsis were identified during the study period. None was bacteremic or required intensive care unit admission. CONCLUSIONS: Single dose ertapenem prophylaxis did not appear to have a significant selective effect on fecal colonization with carbapenem resistant Enterobacteriaceae or other ertapenem resistant gram-negative organisms in this outpatient group. It is highly effective prophylaxis for transrectal ultrasound guided prostate biopsy. In the right setting ertapenem may represent a useful prophylactic option to prevent post-transrectal ultrasound guided prostate biopsy sepsis.
Asunto(s)
Antibacterianos/uso terapéutico , Profilaxis Antibiótica , Farmacorresistencia Bacteriana , Ertapenem/uso terapéutico , Biopsia Guiada por Imagen , Recto/microbiología , Anciano , Enterobacteriaceae/efectos de los fármacos , Enterobacteriaceae/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Próstata/patología , Recto/efectos de los fármacos , Ultrasonografía IntervencionalRESUMEN
Serology is now a well-established diagnostic tool for the diagnosis of COVID-19 infections in New Zealand. Using local and international experience, we provide an overview of serological response to infection and vaccination as well as the use and interpretation of antibody tests in our setting. We also discuss the potential future role of post-vaccination serology testing as a correlate of immunity. We conclude that, given the pitfalls of testing, clinical microbiologist advice is necessary for interpretation of high-consequence cases.
Asunto(s)
Prueba Serológica para COVID-19 , COVID-19/diagnóstico , Humanos , Nueva Zelanda , SARS-CoV-2RESUMEN
Serology is now a well-established diagnostic tool for the diagnosis of COVID-19 infections in New Zealand. Using local and international experience, we provide an overview of serological response to infection and vaccination as well as the use and interpretation of antibody tests in our setting. We also discuss the potential future role of post-vaccination serology testing as a correlate of immunity. We conclude that, given the pitfalls of testing, clinical microbiologist advice is necessary for interpretation of high-consequence cases.
Asunto(s)
Prueba Serológica para COVID-19 , COVID-19/diagnóstico , COVID-19/inmunología , Humanos , Nueva ZelandaRESUMEN
Community transmission of influenza A pandemic (H1N1) 2009 was followed by high rates of hospital admissions in the Wellington region of New Zealand, particularly among Maori and Pacific Islanders. These findings may help health authorities anticipate the effects of pandemic (H1N1) 2009 in other communities.
Asunto(s)
Subtipo H1N1 del Virus de la Influenza A , Gripe Humana/epidemiología , Nativos de Hawái y Otras Islas del Pacífico/estadística & datos numéricos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Brotes de Enfermedades/estadística & datos numéricos , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Lactante , Tiempo de Internación , Masculino , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Adulto JovenRESUMEN
Rothia aeria is a recently described Gram-positive rod from the family Micrococcaceae. An elderly woman with rheumatoid arthritis and dental abscesses who was undergoing immunosuppression had R. aeria isolated from synovial fluid. This report characterizes this rare organism and contributes to the literature on its pathogenicity and likely oral source.
Asunto(s)
Infecciones por Actinomycetales/diagnóstico , Bacteriemia/diagnóstico , Micrococcaceae/aislamiento & purificación , Líquido Sinovial/microbiología , Infecciones por Actinomycetales/tratamiento farmacológico , Infecciones por Actinomycetales/microbiología , Anciano de 80 o más Años , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Artritis Reumatoide/complicaciones , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Caries Dental/complicaciones , Femenino , Humanos , Pruebas de Sensibilidad Microbiana , Micrococcaceae/efectos de los fármacos , Micrococcaceae/genética , Técnicas de Amplificación de Ácido Nucleico , Fenotipo , ARN Ribosómico 16S/genética , Articulación del HombroRESUMEN
New Zealand could be the first country in the world to eliminate tuberculosis (TB). We propose a TB elimination strategy based on the eight-point World Health Organization (WHO) action framework for low incidence countries. Priority actions recommended by the WHO include 1) ensure political commitment, funding and stewardship for planning and essential services; 2) address the most vulnerable and hard-to-reach groups; 3) address special needs of migrants and cross-border issues; 4) identify active TB and undertake screening for latent tuberculosis infection (LTBI) in recent TB contacts and selected high-risk groups, and provide appropriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control. In New Zealand, central government needs to take greater responsibility for TB policy and programme governance. Urgent action is required to prevent TB in higher risk groups including Maori communities, and to enable immigration screening to detect and treat LTBI. Clinical services need to be supported to implement new guidelines for LTBI that enable better targeting of screening and shorter, safer treatment regimens. Access to WHO recommended treatment regimens needs to be guaranteed for drug-resistant TB. Better use of existing data could better define priority areas for action and assist in the evaluation of current control activities. Access to GeneXpert® MTB-RIF near the point of care and whole genome sequencing nationally would greatly improve clinical and public health management through early identification of drug resistance and outbreaks. New Zealand already has a world-class TB research community that could be better deployed to assist high-incidence countries through research and training.
Asunto(s)
Erradicación de la Enfermedad , Tuberculosis/prevención & control , Humanos , Tamizaje Masivo , Nativos de Hawái y Otras Islas del Pacífico , Nueva Zelanda , Salud Pública , Vigilancia en Salud Pública , Tuberculosis/epidemiología , Tuberculosis/transmisiónRESUMEN
BACKGROUND: Legionnaires' disease is under-diagnosed because of inconsistent use of diagnostic tests and uncertainty about whom to test. We assessed the increase in case detection following large-scale introduction of routine PCR testing of respiratory specimens in New Zealand. METHODS: LegiNZ was a national surveillance study done over 1-year in which active case-finding was used to maximise the identification of cases of Legionnaires' disease in hospitals. Respiratory specimens from patients of any age with pneumonia, who could provide an eligible lower respiratory specimen, admitted to one of 20 participating hospitals, covering a catchment area of 96% of New Zealand's population, were routinely tested for legionella by PCR. Additional cases of Legionnaires' disease in hospital were identified through mandatory notification. FINDINGS: Between May 21, 2015, and May 20, 2016, 5622 eligible specimens from 4862 patients were tested by PCR. From these, 197 cases of Legionnaires' disease were detected. An additional 41 cases were identified from notification data, giving 238 cases requiring hospitalisation. The overall incidence of Legionnaires' disease cases in hospital in the study area was 5·4 per 100â000 people per year, and Legionella longbeachae was the predominant cause, found in 150 (63%) of 238 cases. INTERPRETATION: The rate of notified disease during the study period was three-times the average over the preceding 3 years. Active case-finding through systematic PCR testing better clarified the regional epidemiology of Legionnaires' disease and uncovered an otherwise hidden burden of disease. These data inform local Legionnaires' disease testing strategies, allow targeted antibiotic therapy, and help identify outbreaks and effective prevention strategies. The same approach might have similar benefits if applied elsewhere in the world. FUNDING: Health Research Council of New Zealand.
Asunto(s)
Brotes de Enfermedades/estadística & datos numéricos , Enfermedad de los Legionarios/diagnóstico , Enfermedad de los Legionarios/epidemiología , Vigilancia de la Población , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Notificación de Enfermedades , Femenino , Humanos , Incidencia , Legionella pneumophila/aislamiento & purificación , Masculino , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Reacción en Cadena de la Polimerasa , Adulto JovenRESUMEN
Paradoxical reactions are immune-mediated exacerbations of disease triggered by tuberculosis treatment. Paradoxical reactions involving the central nervous system may be life threatening. Infliximab (tumor necrosis factor antibody) profoundly inhibits cellular immune responses to Mycobacterium tuberculosis. We describe a case in which infliximab was used to control steroid-resistant tuberculosis paradoxical reaction involving the central nervous system.
Asunto(s)
Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Encéfalo/inmunología , Factores Inmunológicos/uso terapéutico , Ganglios Linfáticos/inmunología , Tuberculosis/tratamiento farmacológico , Adulto , Encéfalo/efectos de los fármacos , Encéfalo/patología , Femenino , Cabeza/diagnóstico por imagen , Humanos , Infliximab , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/patología , Mycobacterium tuberculosis/inmunología , Radiografía , Esteroides/uso terapéuticoRESUMEN
AIM: To assess the impact of the introduction of rotavirus vaccination in New Zealand at a regional and national level, underlining the utility of a passively collected laboratory dataset. METHOD: Retrospective laboratory data for rotavirus testing from Wellington and Hutt Hospitals from 1 January 2010 to 31 December 2016, matched with hospital admissions data of children under 5years of age with gastroenteritis primary and secondary coded admissions. The second part of the study examined the national dataset of primary coded hospital gastroenteritis admissions from the same period. RESULTS: Rotavirus testing was performed in 1054 (64.1%) of the 1645 gastroenteritis admissions to Wellington and Hutt Hospitals. Four hundred and nine of these tests (38.8%) were positive. Children who were not given a primary code of gastroenteritis accounted for 5.7% of rotavirus admissions. The estimated annual rotavirus hospitalisation rate in the Hutt and Wellington regions for children under 5years during the pre-vaccination period was 427.1 per 100,000. In the post-vaccination period (2015-2016), there was a 94.6% reduction in confirmed rotavirus gastroenteritis hospitalisations with only 8 confirmed cases. The total number of gastroenteritis admissions declined by 51.4%. On a national scale, there was a decline of 34.4% in the average annual number of gastroenteritis admissions and the number of coded rotavirus admissions was 87.1% lower than the pre-vaccination average. CONCLUSION: The non-restrictive continuous approach to rotavirus testing has provided a detailed description of the epidemiology of rotavirus gastroenteritis hospitalisations in the Wellington and Hutt regions. Rotavirus vaccination introduced on the crest of a peak in rotavirus cases has lead to a marked reduction in the number of admissions with gastroenteritis in New Zealand in the two years following vaccine introduction. The national figures likely underestimate the impact of the vaccine.
Asunto(s)
Gastroenteritis/epidemiología , Infecciones por Rotavirus/epidemiología , Vacunas contra Rotavirus , Vacunación/estadística & datos numéricos , Preescolar , Infección Hospitalaria/epidemiología , Bases de Datos Factuales , Femenino , Gastroenteritis/virología , Hospitalización , Humanos , Programas de Inmunización , Lactante , Recién Nacido , Laboratorios , Masculino , Nueva Zelanda/epidemiología , Estudios Retrospectivos , Infecciones por Rotavirus/virología , Vacunas contra Rotavirus/administración & dosificación , Programas Informáticos , Estadística como AsuntoRESUMEN
Streptococcus gallinaceus is a newly described species of viridans streptococci, previously only identified as causing disease in broiler chickens. This organism was recovered in pure culture from blood taken from a New Zealand abattoir worker presenting with a febrile illness. This first report of bacteraemia caused by S. gallinaceus in a human may help the understanding of the ecology of this recently described organism.
Asunto(s)
Fiebre/microbiología , Enfermedades Profesionales/microbiología , Infecciones Estreptocócicas/diagnóstico , Streptococcus/crecimiento & desarrollo , Mataderos , Antibacterianos/uso terapéutico , ADN Bacteriano/química , ADN Bacteriano/genética , Fiebre/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Nueva Zelanda , Reacción en Cadena de la Polimerasa , ARN Ribosómico 16S/química , ARN Ribosómico 16S/genética , Análisis de Secuencia de ADN , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/microbiología , Streptococcus/genéticaRESUMEN
Contemporary diagnostic microbiology is increasingly adopting molecular methods as front line tests for a variety of samples. This trend holds true for detection of enteric pathogens (EP), where nucleic acid amplification tests (NAAT) for viruses are well established as the gold standard, and an increasing number of commercial multi-target assays are now available for bacteria and parasites. NAAT have significant sensitivity and turnaround time advantages over traditional methods, potentially returning same-day results. Multiplex panels offer an attractive 'one-stop shop' that may provide workflow and cost advantages to laboratories processing large sample volumes. However, there are a number of issues which need consideration. Reflex culture is required for antibiotic susceptibility testing and strain typing when needed for food safety and other epidemiological investigations. Surveillance systems will need to allow for differences in disease incidence due to the enhanced sensitivity of NAAT. Laboratories should be mindful of local epidemiology when selecting which pathogens to include in multiplex panels, and be thoughtful regarding which pathogens will not be detected. Multiplex panels may not be appropriate in certain situations, such as hospital-onset diarrhoea, where Clostridium difficile testing might be all that is required, and laboratories may wish to retain the flexibility to run single tests in such situations. The clinical impact of rapid results is also likely to be relatively minor, as infective diarrhoea is a self-limiting illness in the majority of cases. Laboratories will require strategies to assist users in the interpretation of the results produced by NAAT, particularly where pathogens are detected at low levels with uncertain clinical significance. These caveats aside, faecal NAAT are increasingly being used and introduce a new era of diagnosis of gastrointestinal infection.
Asunto(s)
Infecciones Bacterianas/diagnóstico , Enfermedades del Sistema Digestivo/microbiología , Técnicas Microbiológicas , Técnicas de Diagnóstico Molecular , Virosis/diagnóstico , Técnicas de Cultivo de Célula , Enfermedades del Sistema Digestivo/diagnóstico , Humanos , Técnicas Microbiológicas/normas , Técnicas de Diagnóstico Molecular/normasAsunto(s)
Sarampión/inmunología , Diagnóstico Prenatal/métodos , Rubéola (Sarampión Alemán)/diagnóstico , Serología/métodos , Adulto , Epidemias/prevención & control , Femenino , Humanos , Inmunoglobulina G/inmunología , Sarampión/epidemiología , Nueva Zelanda/epidemiología , Nueva Zelanda/etnología , Embarazo/sangre , Rubéola (Sarampión Alemán)/inmunologíaAsunto(s)
Farmacorresistencia Bacteriana , Infecciones por VIH/prevención & control , Disparidades en el Estado de Salud , Hepatitis C/tratamiento farmacológico , Programas de Inmunización , Infectología , Infecciones por VIH/tratamiento farmacológico , Humanos , Infecciones , Nativos de Hawái y Otras Islas del Pacífico , Nueva ZelandaRESUMEN
The aims of this survey were (i) to determine the prevalence of extended-spectrum beta-lactamases (ESBLs) among urinary Escherichia coli and Klebsiella spp. in New Zealand (NZ), (ii) to identify the relative prevalence of ESBL types and (iii) to investigate clonality among ESBL-producing E. coli and Klebsiella spp. During a 4-week period in 2006, 86% of NZ hospital and community diagnostic microbiology laboratories participated in the survey and referred isolates to the national reference laboratory. A total of 86 ESBL-producing isolates were identified, comprising 55 E. coli and 31 Klebsiella spp. (all Klebsiella pneumoniae), equating to prevalence rates of 0.7% and 4.2%, respectively. The majority of the ESBL-producing E. coli (80.0%) and K. pneumoniae (58.6%) were reported to be from community-acquired urinary tract infections. CTX-M-15 and CTX-M-14 accounted for 75.9% and 13.3%, respectively, of the ESBL types identified. A novel ESBL, designated CTX-M-68, was identified. Most CTX-M-15-producing isolates were multiresistant to three or more antibiotic classes. Pulsed-field gel electrophoresis typing identified a wide diversity of strains among the ESBL-producing E. coli, whereas the K. pneumoniae were more clonal. The results of this survey show that the prevalence of ESBLs has increased in recent years in NZ, that CTX-M ESBLs are almost wholly dominant and that ESBL-producing organisms are already established as community-acquired pathogens.